Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680451 | 0.81 | HSD11B1 (0.43) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL30900827 | 0.81 | HSD11B1 (0.43) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL3451372 | 0.81 | HSD11B1 (0.43) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL3038070 | 0.78 | DHFR (0.44) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL13127431 | 0.78 | HSD11B1 (0.43) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL3184997 | 0.78 | DHFR (0.53) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL7233566 | 0.78 | DHFR (0.48) | HSD11B1DHFRMEN1KMT2AKDM4C | |
| SCHEMBL3500438 | 0.78 | TNK2 (0.44) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL23907104 | 0.77 | DHFR (0.37) | HSD11B1DHFRTNK2NPC1RAB9A | |
| SCHEMBL5618972 | 0.77 | MEN1 (0.43) | HSD11B1DHFRNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| EP-3041855-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-07-13 | — | — | EP | disclosed |
| WO-2016030335-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016030335-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2016-03-03 | — | — | WO | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | HSD11B1 757/4885DHFR 29/4885OPRL1 30/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | HSD11B1 2081/4885DHFR 446/4885OPRL1 2076/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | HSD11B1 893/4885DHFR 34/4885OPRL1 23/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | HSD11B1 893/4885DHFR 34/4885OPRL1 23/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | HSD11B1 893/4885DHFR 34/4885OPRL1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.